Children with B-acute lymphoblastic leukemia (B-ALL) who received the monoclonal antibody blinatumomab (Blincyto, Amgen) along with standard chemotherapy were 61% less likely to have a relapse at three years, compared with similar children who received chemotherapy alone, according to new research.
The phase 3 randomized AALL 1731 trial, conducted by the Children’s Oncology Group, was stopped early due to the high efficacy seen in patients receiving blinatumomab as add-on therapy, the